ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug
I'm LongbridgeAI, I can summarize articles.ImmunityBio received UAE marketing authorization for its immunotherapy drug ANKTIVA, covering two indications: non-muscle invasive bladder cancer (NMIBC) and metastatic non-small cell lung cancer (NSCLC). This approval makes the UAE the fifth jurisdiction to approve the treatment, expanding its global footprint. The NMIBC approval is noted as the broadest globally, allowing use across the entire disease spectrum. For NSCLC, it offers a new option for patients progressing after standard treatments. Following the news, ImmunityBio shares rose 5.49%.
The Emirates Drug Establishment (EDE) in the United Arab Emirates on Thursday approved ImmunityBio Inc.’s (NASDAQ:IBRX) immunotherapy drug, ANKTIVA.
The regulatory action covers two distinct indications, making the UAE the fifth jurisdiction worldwide to approve the treatment and expanding its global footprint to 34 countries.
Read Also: ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug
Broadest NMIBC Approval Globally
The UAE’s authorization for non-muscle invasive bladder cancer (NMIBC) represents the most comprehensive approval for ANKTIVA to date.
It permits a 0.4 mg intravesical dose combined with BCG for adult patients with BCG-unresponsive NMIBC.
Notably, this is the first authorization worldwide to cover the entire disease spectrum, encompassing carcinoma in situ (CIS) and papillary disease, whether occurring together or independently.
Historically, patients failing BCG therapy faced high progression risks and often relied on radical cystectomy as the standard alternative.
Clinical evidence from the QUILT-3.032 trial showed a 71% complete response rate in the CIS cohort, extending beyond 54 months.
In the papillary-only cohort, patients achieved a 58.2% disease-free survival rate at 12 months and an 83% cystectomy-free rate at 36 months.
Addressing Metastatic NSCLC Needs
Additionally, the EDE authorized a 1.2 mg subcutaneous dose of ANKTIVA in combination with immune checkpoint inhibitors for adults with metastatic non-small cell lung cancer (NSCLC).
The approval applies to patients whose disease progressed on or after standard treatments, including checkpoint inhibitor failure.
Checkpoint inhibitor resistance remains a significant hurdle in NSCLC, traditionally resulting in poor survival outcomes.
By activating memory T cells and natural killer cells, ANKTIVA is designed to restore anti-tumor immunity.
In the QUILT-3.055 trial, checkpoint-refractory advanced NSCLC patients recorded a median overall survival of 14.6 months, providing a vital new therapy option for those with limited alternatives.
IBRX Stock Price Activity: ImmunityBio shares were up 5.49% at $7.20 at the time of publication Thursday, according to Benzinga Pro data.
Read Also: Tucker Carlson Calls Anthony Fauci 'A Sad and Terrified Old Man' After He Pleads the Fifth Over 100 Times in Fierce Senate Showdown On COVID Origins
Photo by Tigarto via Shutterstock